A biosensor for the detection of hepatitis B antibodies in clinical saliva was developed. Compared to conventional analysis of blood serum, it offers the advantage of noninvasive collection of samples. Detection of biomarkers in saliva imposes two major challenges associated with the low analyte concentration and increased surface fouling. The detection of minute amounts of hepatitis B antibodies was performed by plasmonically amplified fluorescence sandwich immunoassay. To have access to specific detection, we prevented the nonspecific adsorption of biomolecules present in saliva by brushes of poly[(N-(2-hydroxypropyl) methacrylamide)-co-(carboxybetaine methacrylamide)] grafted from the gold sensor surface and post modified with hepatitis B surface antigen. Obtained results were validated against the response measured with ELISA at a certified laboratory using serum from the same patients.

• MeSH
• biologické markery analýza   MeSH
• biosenzitivní techniky metody   MeSH
• fluorescenční spektrometrie MeSH
• hepatitida B - antigeny povrchové chemie   imunologie   MeSH
• hepatitida B - protilátky analýza   krev   imunologie   MeSH
• imobilizované proteiny chemie   imunologie   MeSH
• imunoanalýza MeSH
• lidé MeSH
• polymery chemie   MeSH
• povrchová plasmonová rezonance MeSH
• sliny metabolismus   MeSH
• zlato chemie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• biologické markery MeSH
• hepatitida B - antigeny povrchové MeSH
• hepatitida B - protilátky MeSH
• imobilizované proteiny MeSH
• polymery MeSH
• zlato MeSH

Seroprevalence data on viral hepatitis in the general population vary widely. The aim of this study was to determine the prevalence of hepatitis A (HAV), hepatitis B (HBV) and hepatitis C (HCV) viruses in the general Croatian adult population undergoing routine check-ups. The seroprevalence of anti-HAV, anti-HBc and anti-HCV was 40.5%, 7.0% and 0.9%, respectively. HBsAg was found in 0.7% and anti-HBs antibodies in 24.4% of participants. Gender was not associated with HAV, HBV or HCV seropositivity. HAV and HBV seropositivity increased progressively with age (HAV from 11.7% to 90.4%, p < 0.001; HBV from 1.7% to 15.8%, p < 0.001). Participants from rural areas showed a significantly higher HBV seroprevalence rate than those from urban areas (10.7% vs. 6.1%, p = 0.007). Results of univariate and multiple logistic regression showed that older age was a significant predictor for both HAV and HBV seropositivity while rural place of residence was a significant predictor for HBV seropositivity.

• MeSH
• diagnostické testy rutinní MeSH
• dospělí MeSH
• fyzikální vyšetření metody   MeSH
• hepatitida A - protilátky krev   imunologie   MeSH
• hepatitida B - protilátky krev   imunologie   MeSH
• hepatitida C - protilátky krev   imunologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• prevalence MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• séroepidemiologické studie MeSH
• virová hepatitida u lidí krev   epidemiologie   imunologie   MeSH
• zdraví ve městech statistika a číselné údaje   MeSH
• zdraví venkovských oblastí statistika a číselné údaje   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Chorvatsko epidemiologie   MeSH
• Názvy látek
• hepatitida A - protilátky MeSH
• hepatitida B - protilátky MeSH
• hepatitida C - protilátky MeSH

BACKGROUND: Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown. PATIENTS AND METHODS: A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc). RESULTS: The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child). CONCLUSION: Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence.

• MeSH
• čas MeSH
• dítě MeSH
• hepatitida - antigeny krev   imunologie   MeSH
• hepatitida B - protilátky krev   imunologie   MeSH
• hepatitida B imunologie   prevence a kontrola   virologie   MeSH
• kojenec MeSH
• lidé MeSH
• mladiství MeSH
• následné studie MeSH
• novorozenec MeSH
• očkovací schéma MeSH
• předškolní dítě MeSH
• těhotenství MeSH
• vakcína proti hepatitidě B aplikace a dávkování   imunologie   MeSH
• vakcinace MeSH
• vertikální přenos infekce prevence a kontrola   MeSH
• virus hepatitidy B imunologie   MeSH
• Check Tag
• dítě MeSH
• kojenec MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• novorozenec MeSH
• předškolní dítě MeSH
• těhotenství MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• hepatitida - antigeny MeSH
• hepatitida B - protilátky MeSH
• vakcína proti hepatitidě B MeSH

Using the Praha strain of vaccinia virus (VV) two double recombinant VVs expressing the surface and capsid HBV proteins (HBsAg and HBcAg) under the control of the P7.5 promoter were constructed. In the first construct the gene coding for HBsAg was inserted into the HindIII J fragment (TK gene) and the gene coding for HBcAg was inserted into the HindIII M fragment (host range, K1L gene) of the VV genome. To test whether the expression of the foreign genes was influenced by the insertion site, in the second construct their locations were inversely changed. When compared with single VV-HBV recombinants expressing either HBsAg or HBcAg, the double recombinants expressed in vitro approximately the same amounts of the respective antigens. The particles formed by either HBsAg or HBcAg expressed by recombinant viruses, were isolated and examined by electron microscopy. Particles composed of both HBsAg and HBcAg were not detected in cultures infected with one of the double recombinants. The residual virulence in 3-week-old mice of the single recombinants was not markedly altered by the insertion of the second gene. The immunogenicity in mice of both the single and double recombinants was comparable and was not influenced by the location of the HBV genes in VV genome, as revealed by antibodies developed against the respective antigens.

• MeSH
• buněčné linie MeSH
• DNA virů MeSH
• hepatitida B - antigeny jádrové genetika   imunologie   metabolismus   MeSH
• hepatitida B - antigeny povrchové genetika   imunologie   metabolismus   MeSH
• hepatitida B - protilátky imunologie   MeSH
• imunoblotting MeSH
• klonování DNA MeSH
• lidé MeSH
• molekulární sekvence - údaje MeSH
• myši MeSH
• rekombinantní proteiny genetika   imunologie   metabolismus   MeSH
• sekvence nukleotidů MeSH
• virulence MeSH
• virus vakcinie genetika   patogenita   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• DNA virů MeSH
• hepatitida B - antigeny jádrové MeSH
• hepatitida B - antigeny povrchové MeSH
• hepatitida B - protilátky MeSH
• rekombinantní proteiny MeSH

Several vaccinia virus recombinants inducing the synthesis of the middle surface (M) protein of hepatitis B virus (HBV) were constructed. One of them, denoted v137, was examined in some detail. The virus replicated nearly to the same extent in various cell lines, viz. human embryo diploid fibroblast LEP and MRC-5 cells, rabbit embryo fibroblast REF cells, TK- rat RAT-2 cells, and green monkey CV-1 cells. However, the production of M protein was found considerably lower in the human LEP and MRC-5 than in the other cells examined. In addition, the kinetics of M formation were different in these two cell systems, LEP cells lagging significantly behind CV-1 cells. The low-level production of M protein in LEP cells was not increased by repeated v137 passages in LEP cells, nor by a passage in a laboratory worker accidentally infected with the v137 virus, nor by shortening the leader sequence preceding the translation initiation codon. The greater part of the M antigen was found to be cell associated, more so in the cells of human than monkey origin. From the major HBV S antigen (HBsAg) isolated from the plasma of chronically infected subjects, the antigen released by cell destruction differed by binding to polymerized human albumin. This property was utilized in ELISA to detect anti-preS2 antibody. Rabbits inoculated intradermally with the v137 virus developed antibodies reactive in this assay as well as with a synthetic peptide corresponding in the amino acids 14-34 of the NH2 terminus of the HBsAg preS2 region.

• MeSH
• buněčné linie MeSH
• Cercopithecus aethiops MeSH
• diploidie MeSH
• DNA virů MeSH
• ELISA MeSH
• hepatitida B - antigeny povrchové biosyntéza   MeSH
• hepatitida B - protilátky biosyntéza   imunologie   MeSH
• imunoblotting MeSH
• králíci MeSH
• krysa rodu Rattus MeSH
• lidé MeSH
• molekulární sekvence - údaje MeSH
• plazmidy MeSH
• rekombinace genetická * MeSH
• replikace viru MeSH
• sekvence nukleotidů MeSH
• virus vakcinie genetika   růst a vývoj   imunologie   MeSH
• zvířata MeSH
• Check Tag
• králíci MeSH
• krysa rodu Rattus MeSH
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• DNA virů MeSH
• hepatitida B - antigeny povrchové MeSH
• hepatitida B - protilátky MeSH

Rabbit and mouse sera containing anti-idiotype antibodies against a monoclonal and against some polyclonal anti-HBsAg antibodies were prepared. The immunoglobulin fractions of these sera induced the formation of anti-HBsAg antibodies when injected into BALB/c mice. The sera of humans repeatedly immunized with human anti-HBsAg antibodies were shown to contain anti-idiotype antibodies capable of eliciting an anti-HBsAg response in BALB/c mice and Syrian hamsters. Such sera may be a potential source of human anti-idiotype vaccine.

• MeSH
• ELISA MeSH
• hepatitida B - antigeny povrchové imunologie   MeSH
• hepatitida B - protilátky imunologie   MeSH
• hepatitida B imunologie   prevence a kontrola   MeSH
• idiotypy imunologie   MeSH
• králíci MeSH
• lidé MeSH
• monoklonální protilátky MeSH
• myši MeSH
• radioimunoanalýza MeSH
• virové vakcíny * MeSH
• zvířata MeSH
• Check Tag
• králíci MeSH
• lidé MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• hepatitida B - antigeny povrchové MeSH
• hepatitida B - protilátky MeSH
• idiotypy MeSH
• monoklonální protilátky MeSH
• virové vakcíny * MeSH